10-Q · May 12, 2026
Harvard Bioscience's Q1 2026 results reflect continued challenges with revenue declining to $20.8 million, down from $21.8 million year-over-year, while EPS reached a loss of $0.77, significantly missing estimates.…
Earnings analysis · 10-Q
HBIO earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Harvard Bioscience's Q2 2026 revenue increased to $22.727 million, up 8.1% sequentially and 13.6% year over year, while diluted EPS improved materially to negative $0.14 from negative $0.77 in Q1. Results exceeded…
Read full summary
Harvard Bioscience's Q2 2026 revenue increased to $22.727 million, up 8.1% sequentially and 13.6% year over year, while diluted EPS improved materially to negative $0.14 from negative $0.77 in Q1. Results exceeded consensus revenue and EPS estimates. However, the company remained unprofitable, and the provided 10-Q extract contains no segment, balance-sheet, cash-flow, margin, or quantitative guidance disclosures; risk factors were incorporated by reference to the December 31, 2025 Form 10-K.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.14
What stood out
-
Revenue Rebounded
Q2 2026 revenue was $22.727 million, up from $21 million in Q1 2026 and $20 million in Q2 2025, representing sequential growth of approximately 8.1% and year-over-year growth of approximately 13.6%.
-
EPS Loss Narrowed
Diluted EPS improved to negative $0.14 from negative $0.77 in Q1 2026 and negative $0.50 in Q2 2025, although the company remained loss-making.
-
Beat Revenue and EPS Estimates
Revenue exceeded the $21.45 million consensus estimate by $1.277 million, or approximately 6.0%, while EPS of negative $0.14 was $0.01 better than the negative $0.15 estimate.
-
Controls Remained Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, financial reporting.
What to watch
-
Profitability Remains Negative
The company continued to report a loss, with diluted EPS of negative $0.14 in Q2 2026. The filing also states that the risks in the December 31, 2025 Form 10-K remain applicable and that additional unknown or currently immaterial risks could materially adversely affect results.
Management's outlook
The provided 10-Q text does not include quantitative revenue or EPS guidance. Recent media reports reference an increase to 2026 guidance, but no numeric outlook appears in the filing extract.
Earlier filings 4
10-K · March 13, 2026
Harvard Bioscience (HBIO) positions itself as a translational‑medicine enabler, aligning around Preclinical and CMT product families and targeting organoid/3D biology with new platforms (MeshMEA, Incub8, SoHo). 2025…
10-Q · November 6, 2025
Harvard Bioscience reported Q3 2025 revenue of $20,591,000 (down from $21,970,000 in Q3 2024) and GAAP loss per share of $(0.03) compared with $(0.11) a year ago. Gross profit remained healthy at $12,021,000 and the…
10-Q · August 11, 2025
Harvard Bioscience reported Q2 revenue of $20.45M and a GAAP net loss of $2.282M (loss per share $0.05). Gross margin remained healthy at 56.4% while the company recorded improved operating loss versus the prior-year…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.